What is Immunologix?
Immunologix operates at the intersection of bioanalytical science and drug development, providing critical laboratory services that facilitate the progression of complex therapeutic programs. The company distinguishes itself through a comprehensive suite of offerings, including immunogenicity testing, sophisticated cell-based assays, and precise biomarker analysis. By functioning as a strategic partner to biopharmaceutical entities and research organizations, Immunologix leverages a global network of scientific experts to deliver technical solutions that accelerate the path from discovery to clinical application. Their market position is defined by a commitment to customized scientific partnerships, ensuring that clients receive high-fidelity data necessary for navigating the rigorous regulatory landscapes of modern medicine.
How much funding has Immunologix raised?
Immunologix has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in Immunologix
PPP
Public-Private Partnership
What's next for Immunologix?
With this late-stage capital injection, Immunologix is well-positioned to scale its operational capacity and enhance its technical service offerings. The strategic deployment of these funds will likely focus on expanding laboratory throughput and integrating next-generation analytical technologies to meet the increasing demand for high-quality scientific insights. As the biopharmaceutical sector continues to prioritize efficiency in drug development, Immunologix is poised to leverage its current financial backing to deepen its market penetration and solidify its reputation as a premier provider of bioanalytical and biomarker sciences. Future growth will likely be driven by the continued expansion of their global expert team and the pursuit of long-term partnerships with leading research institutions.
See full Immunologix company page
